The short-term and long-term adverse ocular effects of fesoterodine fumarate

Abstract

Aim: To evaluate the short-term and long-term effects of fesoterodine fumarate treatment which is used for overactive bladder (OAB) on pupil diameter (PD), intraocular pressure (IOP) and accommodation amplitude (AA).Method: Ophthalmic examination was performed before and after receiving medication (on the 30th and 90th day) on 120 eyes of 120 women whom were planned to begin anticholinergic treatment (fesoterodine fumarate, 4 mg/day, peroral) for OAB, prospectively. The changes in PD, IOP and AA were analyzed statistically.Results: The mean age of 120 women was 52.06 ± 9.39 years (30–70 years). The mean PD, IOP and AA values were 4.12 ± 0.61 mm (3.00–5.70 mm), 15.58 ± 1.74 mmHg (11–20 mmHg) 2.28 ± 1.26 Diopter (D) (0.50–5.50 D) at baseline; 4.68 ± 0.65 mm (3.20–5.80 mm), 16.11 ± 1.72 mmHg (11–20 mmHg), 1.68 ± 1.04 D (0.25–4.50 D) at 30th day; and 4.28 ± 0.58 mm (3.10–5.70 mm), 16.09 ± 1.96 mmHg (11–19 mmHg), 2.18 ± 1.19 D (0.50–5.00 D) at 90th day, respectively. Although increases in PD values and decreases in AA values were statistically significant (p < 0.001 for each), the changes in IOP values were not as such (p = 0.642). Visual complaint was not observed in any patient.Discussion: The newest anticholinergic medication in women with OAB increased the PD and decreased the AA statistically significantly. Clinically, it seems to be well-tolerated by the patient.